ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Jun 3, 2025 - 06:00
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow